<p>Ironwood Pharmaceuticals（纳斯达克代码：IRWD - 获取免费报告）在周一发布的研究报告中被 Citizens JMP 的分析师从 “跑赢大盘” 评级下调至 “市场表现” 评级，Briefing.com 自动导入报告。</p>
<p>其他一些股票研究分析师最近也对该公司发表了看法。StockNews.com 在 3 月 29 日的研究报告中将 Ironwood Pharmaceuticals 的股票评级从 “持有” 上调至 “买入”。Craig Hallum 在 1 月 22 日的研究报告中将 Ironwood Pharmaceuticals 的目标价格从 10.00 美元下调至 8.00 美元，并对该股票给予 “买入” 评级。最后，JMP Securities 在 1 月 30 日的研究报告中将 Ironwood Pharmaceuticals 的目标价格从 23.00 美元下调至 14.00 美元，并对该股票给予 “跑赢大盘” 评级。四位分析师对该股票给予 “持有” 评级，四位分析师则给予 “买入” 评级。根据 MarketBeat.com 的数据，该股票的共识评级为 “适度买入”，共识目标价格为 8.60 美元。</p>
<p><strong>查看我们对 IRWD 的最新分析</strong></p>
<h2>Ironwood Pharmaceuticals 股价下跌 30.8%</h2>
<p>纳斯达克：IRWD 周一下跌 0.29 美元，报 0.65 美元。该股票交易量为 7,159,342 股，而其平均交易量为 2,469,602 股。Ironwood Pharmaceuticals 的 52 周低点为 0.59 美元，52 周高点为 8.45 美元。该股票的 50 日移动平均线为 1.55 美元，200 日移动平均线为 3.12 美元。该股票的市值为 1.0592 亿美元，市盈率为-21.82，贝塔值为 0.30。</p>
<p>Ironwood Pharmaceuticals（纳斯达克代码：IRWD - 获取免费报告）于 2 月 27 日发布了季度财报。这家生物技术公司报告该季度每股收益为 0.02 美元，低于分析师的共识预期 0.10 美元，差距为 0.08 美元。该公司该季度的收入为 9055 万美元，而分析师预期为 9385 万美元。Ironwood Pharmaceuticals 的净利润率为-0.65%，股本回报率为-0.96%。分析师预测 Ironwood Pharmaceuticals 在当前年度的每股收益将为 0.1 美元。</p>
<h2>内部买卖情况</h2>
<p>在其他新闻中，首席营销官 Michael Shetzline 在 2 月 10 日的交易中出售了 41,269 股公司的股票。股票以平均价格 1.76 美元出售，总交易额为 72,633.44 美元。交易完成后，首席营销官现在持有 554,007 股公司股票，价值约 975,052.32 美元。这笔交易代表其持股减少了 6.93%。该交易已在向证券交易委员会提交的文件中披露，您可以通过此链接访问。此外，首席执行官 Thomas A. Mccourt 在 2 月 10 日的交易中出售了 139,064 股公司的股票。股票以平均价格 1.76 美元出售，总交易额为 244,752.64 美元。交易完成后，首席执行官现在持有 1,160,634 股公司的股票，价值 2,042,715.84 美元。这代表其持股减少了 10.70%。该交易的披露信息可以在这里找到。在过去三个月中，内部人士出售了价值 338,591 美元的 192,381 股公司股票。公司内部人士持有 12.90% 的股票。</p>
<h2>Ironwood Pharmaceuticals 的机构交易</h2>
<p>大型投资者最近对该股票的持仓进行了调整。Point72 Asia Singapore Pte. Ltd.在第四季度购买了 Ironwood Pharmaceuticals 的新股份，价值约 36,000 美元。Journey Strategic Wealth LLC 在第四季度购买了 Ironwood Pharmaceuticals 的新股份，价值 45,000 美元。Catalyst Funds Management Pty Ltd 在第四季度获得了 Ironwood Pharmaceuticals 的新持仓，价值 47,000 美元。Envestnet Asset Management Inc.在第四季度购买了 Ironwood Pharmaceuticals 的新持仓，价值 50,000 美元。最后，Xponance Inc.在第四季度获得了 Ironwood Pharmaceuticals 的新持仓，价值 50,000 美元。</p>
<h2>关于 Ironwood Pharmaceuticals</h2>
<p>（获取免费报告）</p>
<p>Ironwood Pharmaceuticals, Inc.是一家医疗保健公司，专注于胃肠道（GI）产品的开发和商业化。它在美国、墨西哥、日本、沙特阿拉伯和中国以 LINZESS 的名称销售 linaclotide，这是一种用于治疗患有便秘型肠易激综合症或慢性特发性便秘的成人的鸟苷酸酰化酶 C（GC-C）激动剂，同时在加拿大和欧洲国家以 CONSTELLA 的名称销售。</p>
<h2>精选故事</h2>
<ul>
<li>我们更喜欢的五只股票超过 Ironwood Pharmaceuticals</li>
<li>三只值得购买和持有的医疗保健分红股票</li>
<li>第一季度内部人士购买的三只大盘股：买入、卖出或持有</li>
<li>投资于便士股票需要了解的事项</li>
<li>三只在 2025 年市场低迷中逆势而上的新 IPO</li>
<li>现在值得购买的两只金融科技股票和一只需要避免的股票</li>
<li>三只以折扣价交易的高收益分红股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVJXRA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVJXRA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Ironwood Pharmaceuticals 吗？</h2>
<p>在考虑 Ironwood Pharmaceuticals 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Ironwood Pharmaceuticals 并不在名单上。</p>
<p>虽然 Ironwood 医药目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

Ironwood医药

<p>Citizens Jmp 在最近的一份报告中将 Ironwood Pharmaceuticals (NASDAQ:IRWD) 的评级从 “跑赢大盘” 下调至 “市场表现”。其他分析师的观点不一，StockNews.com 将其评级上调至 “买入”，而 Craig Hallum 和 JMP Securities 则下调了目标价格。该股票经历了显著下跌，交易价格下跌 30.8% 至 0.65 美元，市值为 1.0592 亿美元。最近的内部交易显示首席医学官和首席执行官出售了股份，机构投资者也在公司中增持了新股份。Ironwood 专注于胃肠道产品，特别是用于治疗 IBS 的 linaclotide</p>

<p>Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) was downgraded by analysts at Citizens Jmp from an &#34;outperform&#34; rating to a &#34;market perform&#34; rating in a research report issued on Monday,Briefing.com Automated Import reports.</p>
<div class="lb-trans"><p>Ironwood Pharmaceuticals（纳斯达克代码：IRWD - 获取免费报告）在周一发布的研究报告中被 Citizens JMP 的分析师从 “跑赢大盘” 评级下调至 “市场表现” 评级，Briefing.com 自动导入报告。</p>
</div><p>A number of other equities research analysts also recently weighed in on the company. StockNews.com upgraded shares of Ironwood Pharmaceuticals from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note on Saturday, March 29th. Craig Hallum lowered their target price on Ironwood Pharmaceuticals from $10.00 to $8.00 and set a &#34;buy&#34; rating on the stock in a research report on Wednesday, January 22nd. Finally, JMP Securities lowered their target price on shares of Ironwood Pharmaceuticals from $23.00 to $14.00 and set a &#34;market outperform&#34; rating on the stock in a research note on Thursday, January 30th. Four analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $8.60.</p>
<div class="lb-trans"><p>其他一些股票研究分析师最近也对该公司发表了看法。StockNews.com 在 3 月 29 日的研究报告中将 Ironwood Pharmaceuticals 的股票评级从 “持有” 上调至 “买入”。Craig Hallum 在 1 月 22 日的研究报告中将 Ironwood Pharmaceuticals 的目标价格从 10.00 美元下调至 8.00 美元，并对该股票给予 “买入” 评级。最后，JMP Securities 在 1 月 30 日的研究报告中将 Ironwood Pharmaceuticals 的目标价格从 23.00 美元下调至 14.00 美元，并对该股票给予 “跑赢大盘” 评级。四位分析师对该股票给予 “持有” 评级，四位分析师则给予 “买入” 评级。根据 MarketBeat.com 的数据，该股票的共识评级为 “适度买入”，共识目标价格为 8.60 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on IRWD</strong></p>
<div class="lb-trans"><p><strong>查看我们对 IRWD 的最新分析</strong></p>
</div><h2>Ironwood Pharmaceuticals Trading Down 30.8 %</h2>
<div class="lb-trans"><h2>Ironwood Pharmaceuticals 股价下跌 30.8%</h2>
</div><p>NASDAQ:IRWD traded down $0.29 on Monday, hitting $0.65. 7,159,342 shares of the stock were exchanged, compared to its average volume of 2,469,602. Ironwood Pharmaceuticals has a fifty-two week low of $0.59 and a fifty-two week high of $8.45. The stock has a fifty day moving average of $1.55 and a 200-day moving average of $3.12. The stock has a market cap of $105.92 million, a PE ratio of -21.82 and a beta of 0.30.</p>
<div class="lb-trans"><p>纳斯达克：IRWD 周一下跌 0.29 美元，报 0.65 美元。该股票交易量为 7,159,342 股，而其平均交易量为 2,469,602 股。Ironwood Pharmaceuticals 的 52 周低点为 0.59 美元，52 周高点为 8.45 美元。该股票的 50 日移动平均线为 1.55 美元，200 日移动平均线为 3.12 美元。该股票的市值为 1.0592 亿美元，市盈率为-21.82，贝塔值为 0.30。</p>
</div><p>Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.02 earnings per share for the quarter, missing analysts' consensus estimates of $0.10 by ($0.08). The firm had revenue of $90.55 million for the quarter, compared to analyst estimates of $93.85 million. Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%. As a group, analysts predict that Ironwood Pharmaceuticals will post 0.1 earnings per share for the current year.</p>
<div class="lb-trans"><p>Ironwood Pharmaceuticals（纳斯达克代码：IRWD - 获取免费报告）于 2 月 27 日发布了季度财报。这家生物技术公司报告该季度每股收益为 0.02 美元，低于分析师的共识预期 0.10 美元，差距为 0.08 美元。该公司该季度的收入为 9055 万美元，而分析师预期为 9385 万美元。Ironwood Pharmaceuticals 的净利润率为-0.65%，股本回报率为-0.96%。分析师预测 Ironwood Pharmaceuticals 在当前年度的每股收益将为 0.1 美元。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖情况</h2>
</div><p>In other news, CMO Michael Shetzline sold 41,269 shares of the firm's stock in a transaction on Monday, February 10th. The shares were sold at an average price of $1.76, for a total transaction of $72,633.44. Following the transaction, the chief marketing officer now owns 554,007 shares in the company, valued at approximately $975,052.32. This trade represents a 6.93 % decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through this link. Also, CEO Thomas A. Mccourt sold 139,064 shares of the company's stock in a transaction on Monday, February 10th. The stock was sold at an average price of $1.76, for a total transaction of $244,752.64. Following the completion of the sale, the chief executive officer now owns 1,160,634 shares of the company's stock, valued at $2,042,715.84. This represents a 10.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 192,381 shares of company stock worth $338,591. 12.90% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在其他新闻中，首席营销官 Michael Shetzline 在 2 月 10 日的交易中出售了 41,269 股公司的股票。股票以平均价格 1.76 美元出售，总交易额为 72,633.44 美元。交易完成后，首席营销官现在持有 554,007 股公司股票，价值约 975,052.32 美元。这笔交易代表其持股减少了 6.93%。该交易已在向证券交易委员会提交的文件中披露，您可以通过此链接访问。此外，首席执行官 Thomas A. Mccourt 在 2 月 10 日的交易中出售了 139,064 股公司的股票。股票以平均价格 1.76 美元出售，总交易额为 244,752.64 美元。交易完成后，首席执行官现在持有 1,160,634 股公司的股票，价值 2,042,715.84 美元。这代表其持股减少了 10.70%。该交易的披露信息可以在这里找到。在过去三个月中，内部人士出售了价值 338,591 美元的 192,381 股公司股票。公司内部人士持有 12.90% 的股票。</p>
</div><h2>Institutional Trading of Ironwood Pharmaceuticals</h2>
<div class="lb-trans"><h2>Ironwood Pharmaceuticals 的机构交易</h2>
</div><p>Large investors have recently made changes to their positions in the stock. Point72 Asia Singapore Pte. Ltd. bought a new stake in Ironwood Pharmaceuticals during the fourth quarter worth approximately $36,000. Journey Strategic Wealth LLC bought a new stake in shares of Ironwood Pharmaceuticals during the 4th quarter worth $45,000. Catalyst Funds Management Pty Ltd acquired a new position in Ironwood Pharmaceuticals in the 4th quarter valued at $47,000. Envestnet Asset Management Inc. bought a new position in Ironwood Pharmaceuticals in the 4th quarter worth $50,000. Finally, Xponance Inc. acquired a new position in Ironwood Pharmaceuticals during the 4th quarter worth $50,000.</p>
<div class="lb-trans"><p>大型投资者最近对该股票的持仓进行了调整。Point72 Asia Singapore Pte. Ltd.在第四季度购买了 Ironwood Pharmaceuticals 的新股份，价值约 36,000 美元。Journey Strategic Wealth LLC 在第四季度购买了 Ironwood Pharmaceuticals 的新股份，价值 45,000 美元。Catalyst Funds Management Pty Ltd 在第四季度获得了 Ironwood Pharmaceuticals 的新持仓，价值 47,000 美元。Envestnet Asset Management Inc.在第四季度购买了 Ironwood Pharmaceuticals 的新持仓，价值 50,000 美元。最后，Xponance Inc.在第四季度获得了 Ironwood Pharmaceuticals 的新持仓，价值 50,000 美元。</p>
</div><h2>About Ironwood Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 Ironwood Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.</p>
<div class="lb-trans"><p>Ironwood Pharmaceuticals, Inc.是一家医疗保健公司，专注于胃肠道（GI）产品的开发和商业化。它在美国、墨西哥、日本、沙特阿拉伯和中国以 LINZESS 的名称销售 linaclotide，这是一种用于治疗患有便秘型肠易激综合症或慢性特发性便秘的成人的鸟苷酸酰化酶 C（GC-C）激动剂，同时在加拿大和欧洲国家以 CONSTELLA 的名称销售。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Ironwood Pharmaceuticals</li>
<li>The Top 3 Healthcare Dividend Stocks to Buy and Hold</li>
<li>Top 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or Hold</li>
<li>What to Know About Investing in Penny Stocks</li>
<li>3 Hot New IPOs Defying the 2025 Market Slump</li>
<li>2 Fintech Stocks to Buy Now and 1 to Avoid</li>
<li>3 High-Yield Dividend Stocks Trading at a Discount</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更喜欢的五只股票超过 Ironwood Pharmaceuticals</li>
<li>三只值得购买和持有的医疗保健分红股票</li>
<li>第一季度内部人士购买的三只大盘股：买入、卖出或持有</li>
<li>投资于便士股票需要了解的事项</li>
<li>三只在 2025 年市场低迷中逆势而上的新 IPO</li>
<li>现在值得购买的两只金融科技股票和一只需要避免的股票</li>
<li>三只以折扣价交易的高收益分红股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVJXRA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=IRWD"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Ironwood Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Ironwood Pharmaceuticals 吗？</h2>
</div><p>Before you consider Ironwood Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Ironwood Pharmaceuticals 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ironwood Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Ironwood Pharmaceuticals 并不在名单上。</p>
</div><p>While Ironwood Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Ironwood 医药目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Ironwood Pharmaceuticals（纳斯达克股票代码：IRWD）的股票评级被 Citizens Jmp 下调